My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

45.12 -1.09 (-2.37%)

Streaming Delayed Price Updated: 3:43 PM EST, Mar 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

41 42 Next >

Biden To Propose Change To Obamacare To Extend Subsidies For Families: WSJ ↗

April 05, 2022

Via Benzinga

Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May ↗

April 01, 2022

Sanofi SA (NASDAQ: SNY) plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

Via Benzinga

House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month ↗

April 01, 2022

The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare.

Via Benzinga

EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine ↗

March 30, 2022

Via Benzinga

Why Did Truist Lower IGM Biosciences' Price Target? ↗

March 30, 2022

Via Benzinga

Why Is IGM Biosciences (IGMS) Stock Up Today? ↗

March 29, 2022

Here are the various catalysts investors in IGM Biosciences and IGMS stock are watching today as shares more than double.

Via InvestorPlace

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

53 Biggest Movers From Yesterday ↗

March 30, 2022

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide...

Via Benzinga

Mid-Afternoon Market Update: Dow Surges 250 Points; NeoGenomics Shares Slide ↗

March 29, 2022

U.S. stocks traded higher toward the end of trading, with the Dow jumping over 250 points on Tuesday.

Via Benzinga

Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness ↗

March 29, 2022

President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country

Via Benzinga

Mid-Day Market Update: Crude Oil Down 2.5%; IGM Biosciences Shares Jump ↗

March 29, 2022

U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday.

Via Benzinga

36 Stocks Moving In Tuesday's Mid-Day Session ↗

March 29, 2022

Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: IGMS) shares jumped 49.8% to $22.46. Sanofi SA (...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; McCormick Profit Beats Estimates ↗

March 29, 2022

U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning.

Via Benzinga

IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi ↗

March 29, 2022

Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

20 Stocks Moving in Tuesday's Pre-Market Session ↗

March 29, 2022

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY). Guardforce AI Co.,...

Via Benzinga

A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers ↗

March 29, 2022

Pre-open movers

Via Benzinga

Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)

March 28, 2022

Via AB Newswire

Regeneron-Sanofi's Dupixent Significantly Improved Signs, Symptoms In Chronic Itchy Skin Disease ↗

March 28, 2022

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) have presented

Via Benzinga

Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC ↗

March 24, 2022

The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection.

Via Benzinga

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market ↗

March 21, 2022

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA...

Via Benzinga

Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC ↗

March 21, 2022

U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases.

Via Benzinga

Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi ↗

March 18, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Up to 60,000 people in the US with a rare genetic kidney...

Via Benzinga

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets ↗

March 16, 2022

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC ↗

March 16, 2022

The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren&

Via Benzinga

Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates

March 16, 2022

From Seagen Inc.

Via Business Wire

Why Sanofi Shares Are Trading Lower Today ↗

March 14, 2022

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in...

Via Benzinga

JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474 ↗

March 10, 2022

JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says...

Via Benzinga

Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care ↗

March 09, 2022

The IBD/TIPP Poll shows Covid has fallen among Americans' priorities.

Via Investor's Business Daily

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.